Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101,340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis.
Ungar B, Pavel AB, Li R, Kimmel G, Nia J, Hashim P, Kim HJ, Chima M, Vekaria AS, Estrada Y, Xu H, Peng X, Singer GK, Baum D, Mansouri Y, Taliercio M, Guttman-Yassky E. Ungar B, et al. Among authors: kim hj. J Allergy Clin Immunol. 2021 Jan;147(1):394-397. doi: 10.1016/j.jaci.2020.04.055. Epub 2020 May 16. J Allergy Clin Immunol. 2021. PMID: 32428528 Clinical Trial. No abstract available.
Secukinumab responses vary across the spectrum of congenital ichthyosis in adults.
Lefferdink R, Rangel SM, Chima M, Ibler E, Pavel AB, Kim H, Wu B, Abu-Zayed H, Wu J, Jackson K, Singer G, Choate KA, Guttman-Yassky E, Paller AS. Lefferdink R, et al. Among authors: kim h. Arch Dermatol Res. 2023 Mar;315(2):305-315. doi: 10.1007/s00403-022-02325-3. Epub 2022 Feb 26. Arch Dermatol Res. 2023. PMID: 35218370 Free PMC article. Clinical Trial.
101,340 results
You have reached the last available page of results. Please see the User Guide for more information.